Evidence map›Paper›PMID 42774932›Full record

ArticleResearch and practice in thrombosis and haemostasis2026

Zhu Zhang, Haobo Li, Bingzhang Zou, Xiaofan Ji, Yu Zhang, Yuzhi Tao, Linfeng Xi, Kuangxun Li, Huiwen Li, Mengjie Duo and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhu ZhangNational Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Haobo LiNational Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Bingzhang ZouNational Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Xiaofan JiNational Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Yu ZhangNational Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Yuzhi TaoDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China.
Linfeng XiNational Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Kuangxun LiNational Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Huiwen LiDepartment of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Mengjie DuoNational Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Li ZhaoDepartment of Pharmacy, China-Japan Friendship Hospital, Beijing, China.
Xianbo ZuoDepartment of Pharmacy, China-Japan Friendship Hospital, Beijing, China.
Zhenguo ZhaiNational Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Chen WangNational Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
CURES investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Extended direct oral anticoagulant (DOAC) therapy reduces recurrent venous thromboembolism, but clinically relevant bleeding (CRB) remains a safety concern. DOACs exhibit substantial pharmacokinetic variability among individuals, and genetic determinants of bleeding risk during extended anticoagulation remain unclear. Objectives: To explore the association between pharmacogenomic variants and CRB during extended rivaroxaban therapy and explore their potential contribution to bleeding risk prediction in patients with pulmonary embolism (PE). Methods: In phase 1, 633 rivaroxaban-treated PE patients from the multicenter registry with genome-wide genotyping data were included. Thirteen candidate single-nucleotide polymorphisms across 9 genes previously reported to influence DOAC pharmacokinetics were assessed for associations with CRB during extended anticoagulation. In phase 2, 101 PE patients from an independent cohort underwent rivaroxaban plasma concentration measurement and genotyping for pharmacokinetic validation. Results: In phase 1, 70 patients (11.1%) experienced CRB during the 1-year follow-up. Three Conclusion:

Indexed as

Factor Xa InhibitorsHemorrhagePharmacogenomic VariantsPolymorphism, Single NucleotidePulmonary EmbolismRivaroxabanAgedAnticoagulantsATP Binding Cassette Transporter, Subfamily BFemaleGenotypeHumansMaleMiddle AgedRegistriesRisk FactorsABCB1 protein, humanAnticoagulantsATP Binding Cassette Transporter, Subfamily BFactor Xa InhibitorsRivaroxabanDOACsextended anticoagulationpharmacogenomics

Identifiers

PMID42774932
PMCPMC13594809

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.